

Resource Summary Report

Generated by [RRID](#) on Aug 17, 2026

[pLenti-PGK-KRAS4B\(G12V\)](#)

RRID:Addgene_35633

Type: Plasmid

Proper Citation

RRID:Addgene_35633

Plasmid Information

URL: <http://www.addgene.org/35633>

Proper Citation: RRID:Addgene_35633

Insert Name: K-Ras4B(G12V)

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:22341439](#)

Vector Backbone Description: Backbone Marker:Eric Campeau; Backbone Size:10000; Vector Backbone:pLenti-PGK-Hygro; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pLenti-PGK-KRAS4B(G12V)

Relevant Mutation: Glycine 12 to Valine

Record Creation Time: 20220422T222152+0000

Record Last Update: 20260815T081407+0000

Ratings and Alerts

No rating or validation information has been found for pLenti-PGK-KRAS4B(G12V).

No alerts have been found for pLenti-PGK-KRAS4B(G12V).

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Grze? M, et al. (2024) A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. *Cell death & disease*, 15(8), 638.

Collins SE, et al. (2023) Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion. *Molecular biology of the cell*, 34(2), ar9.

Auf der Maur P, et al. (2023) N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K? inhibition in breast cancer. *Cell reports. Medicine*, 4(4), 101002.

Suzuki T, et al. (2022) Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. *Cancer gene therapy*, 29(5), 505.

Shorstova T, et al. (2021) Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. *Molecular cancer therapeutics*, 20(1), 64.

Al-Masri M, et al. (2021) Architectural control of metabolic plasticity in epithelial cancer cells. *Communications biology*, 4(1), 371.

Kharbanda A, et al. (2020) Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis. *Science signaling*, 13(621).

Vaz M, et al. (2017) Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. *Cancer cell*, 32(3), 360.

Kharbanda A, et al. (2017) Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras. *Biochemical and biophysical research communications*, 493(1), 213.

Zhang K, et al. (2017) Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with ?V-Class integrins to promote EMT. *Oncogene*, 36(41), 5681.

de Jong PR, et al. (2016) ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. *Nature communications*, 7, 11551.

Quartuccio SM, et al. (2015) Mutant p53 expression in fallopian tube epithelium drives cell migration. *International journal of cancer*, 137(7), 1528.